30.02 USD
▲-0.43+5.11%
盘后 28.56 0.00%
2026-08-03
市值
$1.85B
市盈率
—
EPS
-24.47
股息率
—
52 周区间
2.45 – 38.33
成交量
551.07K
Beta
1.47
目标价
44.67
52W 低 2.4552W 高 38.33
价格走势
公司简介
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatmen...